GenLeap Bio Secures Tens of Millions in Pre-A Financing Led by Mingxi Capital to Advance Automated and Intelligent One-Stop Gene Services

VCBeat has learned at the earliest opportunity,Suzhou Junji Gene Technology Co., Ltd. (hereinafter referred to as “GENTLEGEN”)Announced the completion of a Pre-A financing round worth tens of millions of RMB, with this round led byMingxi CapitalSole lead investor.

GENTLEGEN, established in July 2022, is dedicated to the application of automated and intelligent biotechnologies. It has built a one-stop gene service technology platform encompassing gene synthesis, oligonucleotide synthesis, Sanger sequencing, high-throughput sequencing, gene editing, and protein expression, thereby facilitating R&D in life sciences and the industrial upgrading of synthetic biology. Over the past year, GENTLEGEN has achieved significant milestone accomplishments. On the basis of realizing scaled revenue, the company has launched fully automated production lines for gene sequencing and synthesis, established a one-stop gene service platform integrating gene synthesis, sequencing, editing, and expression, and completed the construction and operational launch of its Northern Center (Tianjin Laboratory).

GENTLEGEN focuses on developing innovative services based on its routine genetic services, including NGS-based analysis and testing of biologics, AAV vector and mRNA polyA services, sgRNA services for gene-editing therapeutics, siRNA services for nucleic acid drugs, and microbial strain engineering for gene editing. Recently, the company has launched an NGS-based quality analysis and testing platform for biologics, providing professional and comprehensive NGS quality control solutions for nucleic acid and gene therapies at various development stages, thereby safeguarding the safety of biopharmaceutical products.

This round of financing for GENTLEGEN marks another endorsement from downstream industrial partners in the healthcare sector (co-initiated by Mingxi Capital), following earlier support from an industrial partner in the field of industrial automation. Industrial stakeholders in related fields continue to recognize and support GENTLEGEN’s future development.

Sun Jian, Founder and CEO of GENTLEGENStatement: We extend our gratitude to Mingxi Capital for its investment and support. The market for routine genetic services continues to maintain double-digit growth. However, traditional genetic services rely heavily on manual labor, resulting in high and rising labor costs, delivery timelines affected by manual efficiency, and delivery quality impacted by workforce stability. To address these labor-related pain points, the company has developed proprietary fully automated production lines. Furthermore, overseas satellite laboratories are expected to be rapidly deployed, implemented, and replicated through standardized automated production lines. The market for innovative genetic services holds immense future potential. The third wave of pharmaceuticals, centered on nucleic acid drugs and gene therapies, is gaining momentum, creating new opportunities in upstream genetic services. The synthetic biology industry, driven by engineering design principles and genetic modification technologies, is flourishing, thereby stimulating growth in downstream genetic tool services. As demand for innovative drug and synthetic biology services continues to expand, the company is well-positioned to penetrate this incremental market through differentiated technologies. Looking ahead, the company will leverage advancements in artificial intelligence and automation to empower life sciences, accelerate biomedical innovation, and continue contributing to the practical application of synthetic biology.

Chen Hang, Mingxi CapitalGENTLEGEN’s one-stop gene services cover gene writing (synthesis), reading (sequencing), and editing (modification). The company builds its core competitiveness through automation enablement, differentiated technologies, and international expansion. With the continuous development of gene technologies and downstream innovative drugs and synthetic biology, GENTLEGEN is poised to become a leader in the field of innovative gene services. The company’s core team has over ten years of deep expertise in the gene services industry. Its first fully automated production line for gene sequencing and synthesis has recently commenced operations. GENTLEGEN has achieved multiple global and domestic firsts in differentiated technologies, including NGS-based biopharmaceutical analysis, strain engineering, gene editing, and cell-free gene synthesis. Business expansion in the Asia-Pacific region has shown initial success, and the establishment of overseas satellite laboratories is expected to accelerate international growth. In the future, Mingxi Capital will leverage the industrial and capital resources of its co-initiators to support GENTLEGEN’s development.

Mingxi Capital is a professional healthcare investment institution jointly established by the listed company Mingde Biology and Legend Capital. Focusing on investments in the healthcare sector, it prioritizes sub-sectors such as diagnostic devices, life sciences, and consumer health. Guided primarily by fund returns, Mingxi Capital maximizes investment returns through market-oriented operations and proactive industry empowerment. By leveraging the industrial and capital advantages of its shareholders, Mingxi Capital aims to foster the next industry leaders in the life and health sectors through industry empowerment and capital support.